Half the world’s population are at risk of malaria, a life-threatening disease caused by parasites. About 250 million cases are reported each year, resulting in nearly one million deaths.
Over the past century, inappropriate use of anti-malarials has contributed to drug-resistant strains, thereby increasing the prevalence of the disease.
Background and rationale for a multi-stage genetic malaria vaccine
The complex life cycle and antigen variability of the parasite that causes malaria have traditionally presented challenges in the creation of a vaccine. We believe that our potent adenovirus vectors could provide a new answer.
At Okairos, we are collaborating with the University of Oxford on four malaria antigens in various stages of preclinical and clinical development. Our long-term programme is the development of a multigen vaccine targeting the various stages of the parasite lifecycle.